Analysts Offer Insights on Healthcare Companies: Spark Therapeutics (NASDAQ: ONCE) and CymaBay Therapeutics (NASDAQ: CBAY)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spark Therapeutics (NASDAQ: ONCE) and CymaBay Therapeutics (NASDAQ: CBAY) with bullish sentiments.

Spark Therapeutics (NASDAQ: ONCE)

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), with a price target of $94. The company’s shares closed on Friday at $59.36.

According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.5% and a 42.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.

Currently, the analyst consensus on Spark Therapeutics is Strong Buy and the average price target is $79.86, representing a 34.5% upside.

In a report issued on July 11, Jefferies also initiated coverage with a Buy rating on the stock with a $85 price target.
CymaBay Therapeutics (NASDAQ: CBAY)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on CymaBay Therapeutics (NASDAQ: CBAY) today and set a price target of $12. The company’s shares closed on Friday at $5.65, close to its 52-week high of $6.02.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 27.4% and a 50.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.